Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

A continued drive toward innovation will successfully incorporate the role of AI in biopharma – this is key to precision medicine

Jonathan D Grinstein, PhD -April 26, 2023 Big Pharma Leadership Decries the Inflation Reduction Act https://www.genengnews.com/gen-edge/big-pharma-leadership-decries-the-inflation-reduction-act/

By contrast, the panel rallied enthusiastically in favor of the role of artificial intelligence (AI) in drug discovery. Hardy said AI is transforming Genentech’s R&D activities. “We’re at 300 computational scientists at Genentech in a research organization of 2,400—it’s a very large proportion of our workforce that’s comparable in size to our teams of organic chemists,” he said. “We see this as unlocking tremendous amounts of innovation in the future, and we are just starting to realize new types of partnerships that we can have to take advantage of this.” Amgen’s Bradway sang a similar tune. “The protein folding work, starting with AlphaFold in 2021, was a really big moment for us as an organization and has already led to a number of exciting insights that otherwise might have taken a lot longer,” said Bradway. “In the last few weeks, we’re beginning to recognize how large language models can help us be more productive efficiently.” McMurry-Heath focused on AI’s role in improving precision in patient selection in clinical trials. “AI is going to help us with one of our biggest barriers—cost,” she said. “AI is going to shrink clinical trials, allowing us to really pinpoint which patients are needed to prove the new drug or compound is safe and effective and hopefully cut out a lot of the noise. I’ve met CEOs that say 90% of their costs and time going to market is clinical trials. Clinical trials are not without risk to the patients involved, whether they’re in a placebo arm or the treatment. “Whatever knowledge we can use to make sure that we are only testing the smallest number of patients needed to get an answer that’s reproducible and reliable, [that’s what] we should be striving for.”

Sign in to recut, update, or save this card.